AbCelex Technologies Inc has closed on $2m in Series A venture capital financing.
The funds will support research and development of its antibody-based approach to control pathogens in farm animals related to foodborne illnesses.
"Backed by Cultivian Sandbox Ventures, we are well on our way to developing our lead anti-Campylobacter product for poultry,” said Dr Babaei, president and CEO of AbCelex Technologies.
“AbCelex's antibody-based approach to controlling harmful pathogens is poised to have a dramatic impact on human food safety.”
The round was led by Cultivian Sandbox Ventures, LP, a Chicago-based fund.
Dr Meeusen, of Cultivian Sandbox, said: "The team at AbCelex has overcome the difficulties in delivering antimicrobial antibodies through oral administration to farm animals.
“Their feed additive approach will revolutionize the treatment of many foodborne pathogens improving food safety for all of mankind."
AbCelex Technologies, a privately-held Canadian biotechnology company, has also added Ron Meeusen, Matthew Bell, and Paul Dick to the board of directors.